Načítá se...

Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: The assessment of the added therapeutic value of new medicines with a new active substance is hampered by the lack of appropriate comparative information. Though the extent of this information gap is generally perceived as substantial, it has not been quanti...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: van Luijn, Johan C F, Gribnau, Frank W J, Leufkens, Hubert G M
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Science Inc 2007
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2000577/
https://ncbi.nlm.nih.gov/pubmed/17166187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2006.02812.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!